HP
XLRN

Harbourvest Partners’s Acceleron Pharma XLRN Stock Holding History

Harbourvest Partners’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-51,296
Closed -$1.56M – 31
2017
Q2 		$1.56M Hold
51,296
– – 0.67% 10
2017
Q1 		$1.36M Sell
51,296
-54,668
-52% -$1.44M 0.76% 7
2016
Q4 		$2.7M Buy
+105,964
New +$3.36M 1.63% 5
2015
Q1 		– Sell
-51,163
Closed -$1.99M – 28
2014
Q4 		$1.99M Buy
+51,163
New +$1.78M 1.05% 13

Other funds holding XLRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Harbourvest Partners's XLRN Position: Q3 2017 in Review

Harbourvest Partners sold out of Acceleron Pharma (XLRN) in Q3 2017, closing a stake of 51,296 shares — an estimated $1.56M sold.

Harbourvest Partners first reported a position in XLRN in Q4 2014 and held it in 4 quarters. The position peaked at $2.7M in Q4 2016. 149 funds tracked by Wall St. Rank hold XLRN as of Q3 2017.

  • Harbourvest Partners reported no remaining Acceleron Pharma position as of Q3 2017 after selling out during the quarter.
  • Harbourvest Partners sold 51,296 Acceleron Pharma shares in Q3 2017, an estimated $1.56M.
  • Harbourvest Partners first reported a position in Acceleron Pharma in Q4 2014 and held it in 4 quarters.
  • Harbourvest Partners's Acceleron Pharma position peaked at $2.7M in Q4 2016.
  • 149 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2017.

Based on Harbourvest Partners's 13F filing for Q3 2017, filed 14 Nov 2017.